Bacteria in saliva may be indicative of pancreatic cancer

NewsGuard 100/100 Score

Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva compared to healthy controls and even patients with other cancers or pancreatic diseases, according to research presented today at the annual meeting of the American Society for Microbiology. These findings could form the basis for a test to diagnose the disease in its early stages.

"Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer," says Pedro Torres of San Diego State University who presented the research.

In the United States, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%. Unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases, says Torres.

In the study, Torres and his colleagues compared the diversity of saliva bacteria across 131 patients, 63 female and 68 male, being treated at the University of California, San Diego (UCSD) Moores Cancer Center. Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer and 10 disease free. Results showed that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including non-cancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema and Veillonella.

"Our results suggest the presence of a consistently distinct microbial profile for pancreatic cancer," says Torres. "We may be able to detect pancreatic cancer at its early stages by taking individuals' saliva and looking at the ratios of these bacteria."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer